Journal of Microbiology and Biotechnology

  • 제23권9호
  • /
  • Pages.1197-1205
  • /
  • 2013
  • /
  • 1017-7825(pISSN)
  • /
  • 1738-8872(eISSN)
한국미생물·생명공학회 (The Korean Society for Microbiology and Biotechnology)
권호 표지
DOI QR코드

DOI QR Code

Expression, Purification, and Biological Characterization of The Amino-Terminal Fragment of Urokinase in Pichia pastoris

  • Li, Jianping (The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University) ;
  • Lin, Yuli (The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University) ;
  • Zhuang, Hongqin (The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University) ;
  • Hua, Zi-Chun (The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University)
  • 투고 : 2013.05.03
  • 심사 : 2013.06.04
  • 발행 : 2013.09.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Urokinase (uPA) and its receptor (uPAR) play an important role in tumor growth and metastasis. Targeting the excessive activation of this system as well as the proliferation of the tumor vascular endothelial cell would be expected to prevent tumor neovasculature and halt the tumor development. In this regard, the amino-terminal fragment (ATF) of urokinase has been confirmed as effective to inhibit the proliferation, migration, and invasiveness of cancer cells via interrupting the interaction of uPA and uPAR. Previous studies indicated that ATF expressed in Escherichia coli was mainly contained in inclusion bodies and also lacked posttranslational modifications. In this study, the biologically active and soluble ATF was cloned and expressed in Pichia pastoris. The recombinant protein was purified to be homogenous and confirmed to be biologically active. The yield of the active ATF was about 30 mg/l of the P. pastoris culture medium. The recombinant ATF (rATF) could efficiently inhibit angiogenesis, endothelial cell migration, and tumor cell invasion in vitro. Furthermore, it could inhibit in vivo xenograft tumor growth and prolong the survival of tumor-bearing mice significantly by competing with uPA for binding to cell surfaces. Therefore, P. pastoris is a highly efficient and cost-effective expression system for large-scale production of biologically active rATFs for potential therapeutic application.

키워드

참고문헌

  1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. 1997. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72: 1-22. https://doi.org/10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z
  2. Behrendt N, Ronne E, Ploug M, Petri T, Lober D, Nielsen LS, et al. 1990. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J. Biol. Chem. 265: 6453-6460.
  3. Binder BR, Mihaly J, Prager GW. 2007. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb. Haemost. 97: 336-342.
  4. Brondyk WH. 2009. Selecting an appropriate method for expressing a recombinant protein. Methods Enzymol. 463: 131-147. https://doi.org/10.1016/S0076-6879(09)63011-1
  5. Cereghino JL, Cregg JM. 2000. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol. Rev. 24: 45-66. https://doi.org/10.1111/j.1574-6976.2000.tb00532.x
  6. Choong PF, Nadesapillai AP. 2003. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin. Orthop. Relat. Res. S46-S58.
  7. Cregg JM, Tolstorukov I, Kusari A, Sunga J, Madden K, Chappell T. 2009. Expression in the yeast Pichia pastoris. Methods Enzymol. 463: 169-189. https://doi.org/10.1016/S0076-6879(09)63013-5
  8. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. 1985. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44: 139-266. https://doi.org/10.1016/S0065-230X(08)60028-7
  9. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. 2008. Evolving role of uPA/uPAR system in human cancers. Cancer Treat. Rev. 34: 122-136. https://doi.org/10.1016/j.ctrv.2007.10.005
  10. Demain AL, Vaishnav P. 2009. Production of recombinant proteins by microbes and higher organisms. Biotechnol. Adv. 27: 297-306. https://doi.org/10.1016/j.biotechadv.2009.01.008
  11. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. 2000. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 60: 636-643.
  12. Goldstein D, Gofrit O, Nyska A, Benita S. 2007. Anti-HER2 cationic immunoemulsion as a potential targeted drug delivery system for the treatment of prostate cancer. Cancer Res. 67: 269-275. https://doi.org/10.1158/0008-5472.CAN-06-2731
  13. Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, et al. 2000. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J. 14: 1400-1410. https://doi.org/10.1096/fj.14.10.1400
  14. Kim TD, Song KS, Li G, Choi H, Park HD, Lim K, et al. 2006. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 6: 211. https://doi.org/10.1186/1471-2407-6-211
  15. Kobayashi H, Gotoh J, Shinohara H, Moniwa N, Terao T. 1994. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb. Haemost. 71: 474-480.
  16. Koolwijk P, van Erck MG, de Vree WJ, Vermeer MA, Weich HA, Hanemaaijer R, et al. 1996. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J. Cell Biol. 132: 1177-1188. https://doi.org/10.1083/jcb.132.6.1177
  17. Laufs S, Schumacher J, Allgayer H. 2006. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 5: 1760-1771. https://doi.org/10.4161/cc.5.16.2994
  18. Li H, Griscelli F, Lindenmeyer F, Opolon P, Sun LQ, Connault E, et al. 1999. Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice. Hum. Gene Ther. 10: 3045-3053. https://doi.org/10.1089/10430349950016438
  19. Li H, Soria C, Griscelli F, Opolon P, Soria J, Yeh P, et al. 2005. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway. Hum. Gene Ther. 16: 1157-1167. https://doi.org/10.1089/hum.2005.16.1157
  20. Mars WM, Jo M, Gonias SL. 2005. Activation of hepatocyte growth factor by urokinase-type plasminogen activator is ionic strength-dependent. Biochem. J. 390: 311-315. https://doi.org/10.1042/BJ20042028
  21. Mohanam S, Chandrasekar N, Yanamandra N, Khawar S, Mirza F, Dinh DH, et al. 2002. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator. Oncogene 21: 7824-7830. https://doi.org/10.1038/sj.onc.1205893
  22. Moreau P, Voillat L, Benboukher L, Mathiot C, Dumontet C, Robillard N, et al. 2007. Rituximab in CD20 positive multiple myeloma. Leukemia 21: 835-836. https://doi.org/10.1038/sj.leu.2404558
  23. Odekon LE, Sato Y, Rifkin DB. 1992. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J. Cell Physiol 150: 258-263. https://doi.org/10.1002/jcp.1041500206
  24. Pollanen J, Stephens RW, Vaheri A. 1991. Directed plasminogen activation at the surface of normal and malignant cells. Adv. Cancer Res. 57: 273-328. https://doi.org/10.1016/S0065-230X(08)61002-7
  25. Rabbani SA, Gladu J. 2002. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res. 62: 2390-2397.
  26. Shih T, Lindley C. 2006. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin. Ther. 28: 1779-1802. https://doi.org/10.1016/j.clinthera.2006.11.015
  27. Sidenius N, Blasi F. 2003. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 22: 205-222. https://doi.org/10.1023/A:1023099415940
  28. Sun Q, Xu Q, Dong X, Cao L, Huang X, Hu Q, et al. 2008. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy. Int. J. Cancer 123: 942-950. https://doi.org/10.1002/ijc.23537
  29. Sun QM, Cao L, Fang L, Chen C, Dai J, Chen LL, et al. 2005. Expression, purification of human vasostatin120-180 in Escherichia coli, and its anti-angiogenic characterization. Protein Expr. Purif. 39: 288-295. https://doi.org/10.1016/j.pep.2004.10.024
  30. Wang X, Hou M, Tan L, Sun X, Zhang Y, Li P, et al. 2005. A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis. J. Cancer Res. Clin. Oncol. 131: 129-136. https://doi.org/10.1007/s00432-004-0623-2
  31. Zhao G, Yuan C, Bian C, Hou X, Shi X, Ye X, et al. 2006. Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator. Protein Expr. Purif. 49: 71-77. https://doi.org/10.1016/j.pep.2006.05.005

피인용 문헌

  1. Overview of Recent Progress in Protein-Expression Technologies for Small-Molecule Screening vol.19, pp.7, 2014, https://doi.org/10.1177/1087057114520975
  2. Expression and activity analysis of a new fusion protein targeting ovarian cancer cells vol.34, pp.3, 2013, https://doi.org/10.3892/or.2015.4118
  3. Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris vol.35, pp.2, 2013, https://doi.org/10.3892/or.2015.4448